Background: In addition to guiding targeted therapy, tumor profiling may incidentally reveal germline mutations leading to the diagnosis of hereditary cancer predisposition. When somatic and germline analysis is performed in tandem, 4-13% of patients are found to carry a mutation in a cancersusceptibility gene. However, the rate of pathogenic mutations is significantly higher (17.5%) when germline testing is performed subsequent to tumor profiling. We sought to examine the frequency and clinical significance of germline testing subsequent to tumor profiling when performed at separate laboratories.
